PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
8416935-6	1993	However, 1-methyl-4-phenylpyridinium and tetrabenazine, the other principal inhibitor of vesicular amine transport, compete very poorly with reserpine for binding, suggesting that they interact with CGAT at distinct sites.	Tetrabenazine	41-54	solute carrier family 18 member A1	Rattus norvegicus	199-203
7912402-4	1994	COS cell hSVMT expression yielded nanomolar affinities for tetrabenazine and reserpine, micromolar affinities for haloperidol, GBR12909, serotonin, mazindol, nomifensin and d-amphetamine, while dopamine, epinephrine, norepinephrine and histamine each displayed millimolar affinities.	Tetrabenazine	59-72	solute carrier family 18 member A2	Homo sapiens	9-14
8489249-3	1993	Tetrabenazine (TBZ)-displaceable [3H]ketanserin binding was used to label the granular 5-HT transporter.	Tetrabenazine	0-13	solute carrier family 6 member 4	Homo sapiens	87-103
8489249-3	1993	Tetrabenazine (TBZ)-displaceable [3H]ketanserin binding was used to label the granular 5-HT transporter.	Tetrabenazine	15-18	solute carrier family 6 member 4	Homo sapiens	87-103
8313393-2	1993	In psychopharmacologic investigations, the compound shows the properties expected of an MAO inhibitor, antagonizing the effects of reserpine, tetrabenazine, and 5-hydroxytryptophan in rats and mice, and suppressing rapid eye movement sleep in cats.	Tetrabenazine	142-155	monoamine oxidase A	Rattus norvegicus	88-91
1993899-4	1991	Theophylline, tetrabenazine, and angiotensin II also increased the rate of proenkephalin synthesis (three- to eight-fold).	Tetrabenazine	14-27	proenkephalin	Bos taurus	75-88
8473893-8	1993	Additionally, tetrabenazine binding showed a consistent shoulder in the region of synaptophysin.	Tetrabenazine	14-27	synaptophysin	Bos taurus	82-95
1861155-6	1991	Addition of tetrabenazine, an inhibitor of catecholamine uptake into chromaffin vesicles, during radiolabeling and a 6-h chase period caused enhanced proenkephalin processing.	Tetrabenazine	12-25	proenkephalin	Bos taurus	150-163
1970506-7	1990	The tetrabenazine effect on TH and pEK mRNA was reduced by alpha-amanitin, suggesting transcriptionally-mediated regulation.	Tetrabenazine	4-17	tyrosine hydroxylase	Bos taurus	28-30
1970506-7	1990	The tetrabenazine effect on TH and pEK mRNA was reduced by alpha-amanitin, suggesting transcriptionally-mediated regulation.	Tetrabenazine	4-17	proenkephalin	Bos taurus	35-38
3264161-5	1988	Moreover, [3H]MPP+ uptake is blocked by the monoamine transporter inhibitors tetrabenazine and reserpine.	Tetrabenazine	77-90	solute carrier family 18 member A2	Homo sapiens	44-65
35429504-6	2022	As expected, dopamine accumulation was increased with l-DOPA addition or VMAT2-overexpression, and dopamine synthesis decreased further with added dopamine, the VMAT2 inhibitor tetrabenazine or D2 auto-receptor activation with quinpirole, accordingly to the known synaptic effects of these treatments.	Tetrabenazine	177-190	solute carrier family 18 member A2	Rattus norvegicus	161-166
34491372-1	2022	PURPOSE: Deutetrabenazine is a deuterated form of tetrabenazine with a confirmed lower rate of CYP2D6 metabolism of the active metabolites, alpha- and beta-HTBZ.	Tetrabenazine	50-63	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	95-101
34282360-4	2021	Vesicular monoamine transporter2 (VMAT2) inhibitors (Tetrabenazine, Deutetrabenazine, and Valbenazine) are new agents introduced in the last decade for treating some of movement disorders, in particular tardive dyskinesia, Huntington chorea, and Tourette syndrome.	Tetrabenazine	53-66	solute carrier family 18 member A2	Homo sapiens	0-32
34282360-4	2021	Vesicular monoamine transporter2 (VMAT2) inhibitors (Tetrabenazine, Deutetrabenazine, and Valbenazine) are new agents introduced in the last decade for treating some of movement disorders, in particular tardive dyskinesia, Huntington chorea, and Tourette syndrome.	Tetrabenazine	53-66	solute carrier family 18 member A2	Homo sapiens	34-39
3346672-8	1988	Finally, dopamine and 5-hydroxytryptamine depleted from their striatal stores by tetrabenazine were able to displace SR 95191 from the active site of MAO-A.	Tetrabenazine	81-94	monoamine oxidase A	Rattus norvegicus	150-155
3380081-6	1988	Tetrabenazine, an inhibitor of the monoamine transporter of chromaffin granules, displaced [3H]ketanserin binding.	Tetrabenazine	0-13	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	35-56
3380081-14	1988	It is concluded that nonspecific displaceable binding sites of [3H]ketanserin previously described in the striatum are tetrabenazine binding sites associated with the synaptic vesicle monoamine transporter.	Tetrabenazine	119-132	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	184-205
3336349-0	1988	Hydrophobicity of the tetrabenazine-binding site of the chromaffin granule monoamine transporter.	Tetrabenazine	22-35	solute carrier family 18 member A2	Homo sapiens	75-96
3336349-1	1988	The catecholamine uptake inhibitor tetrabenazine (TBZ) binds to a high affinity site on the chromaffin granule membrane, presumably on the monoamine transporter.	Tetrabenazine	35-48	solute carrier family 18 member A2	Homo sapiens	139-160
3336349-1	1988	The catecholamine uptake inhibitor tetrabenazine (TBZ) binds to a high affinity site on the chromaffin granule membrane, presumably on the monoamine transporter.	Tetrabenazine	50-53	solute carrier family 18 member A2	Homo sapiens	139-160
3900292-2	1985	Catecholamine-depleting drugs, such as tetrabenazine, and cyclic nucleotide-elevating drugs, including forskolin, 8-bromo-cyclic AMP, and theophylline, increase chromaffin cell enkephalin-containing peptide levels but fail to increase dopamine beta-hydroxylase.	Tetrabenazine	39-52	dopamine beta-hydroxylase	Homo sapiens	235-260
3951433-5	1986	Transport occurs through the monoamine transporter since it is blocked by the same inhibitors, tetrabenazine and reserpine, and also by the transporter substrates noradrenaline and serotonin.	Tetrabenazine	95-108	solute carrier family 18 member A2	Bos taurus	29-50
3569299-1	1987	The monoamine transporter of chromaffin granule membrane has two distinct high-affinity binding sites for tetrabenazine and reserpine, which can be assayed by [3H]dihydrotetrabenazine and [3H]reserpine binding, respectively.	Tetrabenazine	106-119	solute carrier family 18 member A2	Homo sapiens	4-25
6197309-4	1983	Using a different approach, it was found that dopamine and serotonin released from their stores in rat striatum by tetrabenazine could displace CGP 11305 A from the MAO A active site in vivo, in contrast to clorgyline.	Tetrabenazine	115-128	monoamine oxidase A	Rattus norvegicus	165-170
6183051-8	1982	Reserpine and tetrabenazine depleted 5-HT and partially depleted substance P and TRH in the ventral cord, but had no effect on either methionine-enkephalin or somatostatin.	Tetrabenazine	14-27	thyrotropin releasing hormone	Rattus norvegicus	81-84
6174352-2	1981	Reserpine and tetrabenazine, but not p-chlorophenylalanine caused a partial depletion of ventral spinal cord substance P (SP) and thyrotropin-releasing hormone (TRH).	Tetrabenazine	14-27	tachykinin precursor 1	Homo sapiens	109-120
6174352-2	1981	Reserpine and tetrabenazine, but not p-chlorophenylalanine caused a partial depletion of ventral spinal cord substance P (SP) and thyrotropin-releasing hormone (TRH).	Tetrabenazine	14-27	tachykinin precursor 1	Homo sapiens	122-124
6174352-2	1981	Reserpine and tetrabenazine, but not p-chlorophenylalanine caused a partial depletion of ventral spinal cord substance P (SP) and thyrotropin-releasing hormone (TRH).	Tetrabenazine	14-27	thyrotropin releasing hormone	Homo sapiens	130-159
6174352-4	1981	The rates of loss and recovery of SP and TRH after reserpine and tetrabenazine were different from that of 5-hydroxytryptamine (5-HT), though in the ventral spinal cord these two peptides probably coexist with 5-HT in the terminals of bulbospinal neurones.	Tetrabenazine	65-78	tachykinin precursor 1	Homo sapiens	34-36
6794869-0	1981	[Binding of a tetrabenazine derivative to the monoamine transporter of the chromaffin granule membrane].	Tetrabenazine	14-27	solute carrier family 18 member A2	Homo sapiens	46-67
33038289-5	2021	Both studies confirmed longer half-lives for active metabolites and lower peak-to-trough fluctuations for the sum of the metabolites (total [alpha+beta]-HTBZ) following deutetrabenazine compared with tetrabenazine (3- to 4-fold and 11-fold, respectively) in steady-state conditions.	Tetrabenazine	172-185	amyloid beta precursor protein	Homo sapiens	141-151
32771528-10	2020	On the other hand, while tetrabenazine had mild effects on cFOS counts, it reduced functional connectivity across the entire brain, cortical node degree, and global efficiency.	Tetrabenazine	25-38	FBJ osteosarcoma oncogene	Mus musculus	59-63
32770257-4	2020	OBJECTIVES: Recent studies demonstrated that the atypical DA transport (DAT) inhibitor (S)-CE-123 reversed tetrabenazine-induced motivational deficits, increased progressive ratio (PROG) lever pressing, and increased extracellular DA in the nucleus accumbens.	Tetrabenazine	107-120	solute carrier family 6 member 3	Homo sapiens	72-75
33174440-3	2021	Deutetrabenazine was adapted from an earlier VMAT2 inhibitor, tetrabenazine, by substituting three deuterium isotopes in place of three hydrogen isotopes at the site of metabolic degradation to improve upon the pharmacokinetics of the parent compound.	Tetrabenazine	3-16	solute carrier family 18 member A2	Homo sapiens	45-50
33038289-6	2021	Deutetrabenazine doses estimated to provide total (alpha+beta)-HTBZ exposure comparable to tetrabenazine 25 mg were 11.4-13.2 mg. Food had no effect on exposure to total (alpha+beta)-HTBZ, as measured by AUC.	Tetrabenazine	3-16	amyloid beta precursor protein	Homo sapiens	51-61
33038289-7	2021	Although the total (alpha+beta)-HTBZ Cmax of deutetrabenazine was increased by  50% in the presence of food, it remained lower than that of tetrabenazine.	Tetrabenazine	48-61	amyloid beta precursor protein	Homo sapiens	20-30
30870235-1	2019	OBJECTIVES: The aim of this study was to review our "real-world" experience with the vesicular monoamine transporter 2 (VMAT2) inhibitors tetrabenazine (TBZ), deutetrabenazine (DTBZ), and valbenazine (VBZ) for treatment of hyperkinetic movement disorders.	Tetrabenazine	138-151	solute carrier family 18 member A2	Homo sapiens	85-118
32454050-4	2020	Optimization of the pharmacology of tetrabenazine has since led to the approval of two new VMAT2 inhibitors, deutetrabenazine and valbenazine.	Tetrabenazine	36-49	solute carrier family 18 member A2	Homo sapiens	91-96
32329312-4	2020	Results: Thirteen clinical cases, ten of which involved tetrabenazine, were identified in which VMAT2 inhibitors were prescribed in patients with current or past NMS episodes.	Tetrabenazine	56-69	solute carrier family 18 member A2	Homo sapiens	96-101
31209099-10	2019	Hence, we hypothesize that TBZ facilitates exocytosis by increasing Ca2+ release through the endoplasmic reticulum ryanodine receptor channel (RyR).	Tetrabenazine	27-30	ryanodine receptor 2	Rattus norvegicus	115-141
31209099-10	2019	Hence, we hypothesize that TBZ facilitates exocytosis by increasing Ca2+ release through the endoplasmic reticulum ryanodine receptor channel (RyR).	Tetrabenazine	27-30	ryanodine receptor 2	Rattus norvegicus	143-146
29455579-4	2019	These agents were pharmacologically modified from tetrabenazine, a VMAT2 inhibitor used off-label in the treatment of tardive dyskinesia.	Tetrabenazine	50-63	solute carrier family 18 member A2	Homo sapiens	67-72
30870235-1	2019	OBJECTIVES: The aim of this study was to review our "real-world" experience with the vesicular monoamine transporter 2 (VMAT2) inhibitors tetrabenazine (TBZ), deutetrabenazine (DTBZ), and valbenazine (VBZ) for treatment of hyperkinetic movement disorders.	Tetrabenazine	138-151	solute carrier family 18 member A2	Homo sapiens	120-125
30870235-1	2019	OBJECTIVES: The aim of this study was to review our "real-world" experience with the vesicular monoamine transporter 2 (VMAT2) inhibitors tetrabenazine (TBZ), deutetrabenazine (DTBZ), and valbenazine (VBZ) for treatment of hyperkinetic movement disorders.	Tetrabenazine	153-156	solute carrier family 18 member A2	Homo sapiens	85-118
30198706-3	2019	The development of in vivo imaging radiotracers for VMAT2 is a story of starting with a well-characterized clinically used drug (tetrabenazine) which had a pharmacologically active metabolite: that metabolite that was in stepwise fashion refined and modified to provide both carbon-11 and fluorine-18 labeled VMAT2 radiotracers that are now used for human PET studies of neurodegenerative and psychiatric diseases.	Tetrabenazine	129-142	solute carrier family 18 member A2	Homo sapiens	52-57
30198706-3	2019	The development of in vivo imaging radiotracers for VMAT2 is a story of starting with a well-characterized clinically used drug (tetrabenazine) which had a pharmacologically active metabolite: that metabolite that was in stepwise fashion refined and modified to provide both carbon-11 and fluorine-18 labeled VMAT2 radiotracers that are now used for human PET studies of neurodegenerative and psychiatric diseases.	Tetrabenazine	129-142	solute carrier family 18 member A2	Homo sapiens	309-314
29996061-4	2018	Areas covered: Deutetrabenazine is the first deuterated drug and second drug after tetrabenazine, the classic vesicular monoamine transporter type 2 (VMAT2) inhibitor, to receive approval for the treatment of chorea associated with HD.	Tetrabenazine	18-31	solute carrier family 18 member A2	Homo sapiens	110-148
30306450-3	2018	At present, there are three commercially available VMAT2 inhibitors: tetrabenazine, deutetrabenazine, and valbenazine.	Tetrabenazine	69-82	solute carrier family 18 member A2	Homo sapiens	51-56
29408363-4	2018	In the present work, we evaluated the effect of caffeine on anergia induced by the VMAT-2 inhibitor tetrabenazine (TBZ), which depletes DA.	Tetrabenazine	100-113	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	83-89
29408363-4	2018	In the present work, we evaluated the effect of caffeine on anergia induced by the VMAT-2 inhibitor tetrabenazine (TBZ), which depletes DA.	Tetrabenazine	115-118	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	83-89
29433808-5	2018	Characterization of the VMAT2 inhibitor tetrabenazine, which was identified as a therapeutic agent for TD in older clinical trials, has yielded two distinct pharmacologic strategies to optimize response.	Tetrabenazine	40-53	solute carrier family 18 member A2	Homo sapiens	24-29
29996061-4	2018	Areas covered: Deutetrabenazine is the first deuterated drug and second drug after tetrabenazine, the classic vesicular monoamine transporter type 2 (VMAT2) inhibitor, to receive approval for the treatment of chorea associated with HD.	Tetrabenazine	18-31	solute carrier family 18 member A2	Homo sapiens	150-155
29309800-0	2018	Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions.	Tetrabenazine	63-76	monoamine oxidase B	Homo sapiens	86-91
29484607-5	2018	The vesicular monoamine transporter 2 (VMAT2) inhibitors, which include tetrabenazine, deutetrabenazine, and valbenazine, are considered the treatment of choice for most patients with TD.	Tetrabenazine	72-85	solute carrier family 18 member A2	Homo sapiens	4-37
29484607-5	2018	The vesicular monoamine transporter 2 (VMAT2) inhibitors, which include tetrabenazine, deutetrabenazine, and valbenazine, are considered the treatment of choice for most patients with TD.	Tetrabenazine	72-85	solute carrier family 18 member A2	Homo sapiens	39-44
29484607-6	2018	Deutetrabenazine-a deuterated version of tetrabenazine-and valbenazine, the purified parent product of one of the main tetrabenazine metabolites, are novel VMAT2 inhibitors and the only drugs to receive approval from the US FDA for the treatment of TD.	Tetrabenazine	3-16	solute carrier family 18 member A2	Homo sapiens	156-161
29484607-6	2018	Deutetrabenazine-a deuterated version of tetrabenazine-and valbenazine, the purified parent product of one of the main tetrabenazine metabolites, are novel VMAT2 inhibitors and the only drugs to receive approval from the US FDA for the treatment of TD.	Tetrabenazine	41-54	solute carrier family 18 member A2	Homo sapiens	156-161
29309800-7	2018	These effects of 0.75mg/kg tetrabenazine were attenuated by co-administration of the MAO-B inhibitor deprenyl (selegiline).	Tetrabenazine	27-40	monoamine oxidase B	Homo sapiens	85-90
27819145-4	2016	Areas covered: Since the approval of tetrabenazine, the classic VMAT2 inhibitor, in the treatment of chorea associated with Huntington disease (HD), other VMAT2 inhibitors (e.g. deutetrabenazine and valbenazine) have been studied in the treatment of HD-related chorea, tardive dyskinesia and tics associated with Tourette syndrome.	Tetrabenazine	37-50	solute carrier family 18 member A2	Homo sapiens	64-69
29497277-3	2018	Deutetrabenazine is a deuterated form of tetrabenazine and is a vesicular monoamine transporter 2 (VMAT2) inhibitor.	Tetrabenazine	3-16	solute carrier family 18 member A2	Homo sapiens	64-97
29497277-3	2018	Deutetrabenazine is a deuterated form of tetrabenazine and is a vesicular monoamine transporter 2 (VMAT2) inhibitor.	Tetrabenazine	3-16	solute carrier family 18 member A2	Homo sapiens	99-104
29120264-5	2018	Expert commentary: Inhibitors of presynaptic vesicular monoamine transporter type 2 (VMAT2) that cause striatal dopamine depletion, such as tetrabenazine, deutetrabenazine, and valbenazine, are considered the treatment of choice in patients with chorea.	Tetrabenazine	140-153	solute carrier family 18 member A2	Homo sapiens	45-83
29120264-5	2018	Expert commentary: Inhibitors of presynaptic vesicular monoamine transporter type 2 (VMAT2) that cause striatal dopamine depletion, such as tetrabenazine, deutetrabenazine, and valbenazine, are considered the treatment of choice in patients with chorea.	Tetrabenazine	140-153	solute carrier family 18 member A2	Homo sapiens	85-90
28776237-10	2017	CONCLUSIONS: Based on relative abundance and potency, [+]-beta-HTBZ appears to be the primary contributor to VMAT2 inhibition by TBZ, a finding in contrast with the generally held assertion that [+]-alpha-HTBZ is the major contributor.	Tetrabenazine	64-67	solute carrier family 18 member A2	Homo sapiens	109-114
28776237-11	2017	[-]-alpha-HTBZ, the other abundant TBZ metabolite, has much lower VMAT2 inhibitory potency than [+]-beta-HTBZ, but increased affinity for other CNS targets, which may contribute to off-target effects of TBZ.	Tetrabenazine	11-14	solute carrier family 18 member A2	Homo sapiens	66-71
28404690-4	2017	Radioligand-binding studies were conducted to assess and compare valbenazine, tetrabenazine, and their respective metabolites in their abilities to selectively and potently inhibit [3H]-HTBZ binding to VMAT2 in rat striatal, rat forebrain, and human platelet homogenates.	Tetrabenazine	78-91	solute carrier family 18 member A2	Rattus norvegicus	202-207
28404690-9	2017	In vivo studies measuring ptosis and prolactin secretion in the rat confirmed the specific and dose-dependent interactions of tetrabenazine and R,R,R-HTBZ with VMAT2.	Tetrabenazine	126-139	solute carrier family 18 member A2	Rattus norvegicus	160-165
29080203-1	2017	Oral deutetrabenazine (Austedo ), a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2) that is structurally related to tetrabenazine is approved for the treatment of chorea symptoms associated with Huntington"s disease (HD).	Tetrabenazine	8-21	solute carrier family 18 member A2	Homo sapiens	60-98
29080203-1	2017	Oral deutetrabenazine (Austedo ), a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2) that is structurally related to tetrabenazine is approved for the treatment of chorea symptoms associated with Huntington"s disease (HD).	Tetrabenazine	8-21	solute carrier family 18 member A2	Homo sapiens	100-105
28905625-0	2017	Oral Ingestion and Intraventricular Injection of Curcumin Attenuates the Effort-Related Effects of the VMAT-2 Inhibitor Tetrabenazine: Implications for Motivational Symptoms of Depression.	Tetrabenazine	120-133	solute carrier family 18 member A2	Homo sapiens	103-109
28742396-5	2017	Valbenazine is a modified metabolite of the vesicular monoamine transporter 2 (VMAT-2) inhibitor tetrabenazine, which is approved for the treatment of the hyperkinetic movement disorder, Huntington"s disease.	Tetrabenazine	97-110	solute carrier family 18 member A2	Homo sapiens	44-77
28742396-5	2017	Valbenazine is a modified metabolite of the vesicular monoamine transporter 2 (VMAT-2) inhibitor tetrabenazine, which is approved for the treatment of the hyperkinetic movement disorder, Huntington"s disease.	Tetrabenazine	97-110	solute carrier family 18 member A2	Homo sapiens	79-85
27570189-16	2016	A similar differential secretory dysfunction is observed in CB cells treated with tetrabenazine, a selective inhibitor of the vesicular monoamine transporter 2 (VMAT2).	Tetrabenazine	82-95	solute carrier family 18 member A2	Rattus norvegicus	126-159
27570189-16	2016	A similar differential secretory dysfunction is observed in CB cells treated with tetrabenazine, a selective inhibitor of the vesicular monoamine transporter 2 (VMAT2).	Tetrabenazine	82-95	solute carrier family 18 member A2	Rattus norvegicus	161-166
27819145-6	2016	Expert commentary: Because of differences in pharmacology and pharmacokinetics these new VMAT2 inhibitors promise to be at least as effective as tetrabenazine but with a lower risk of adverse effects, such as sedation, insomnia, depression, parkinsonism, and akathisia.	Tetrabenazine	145-158	solute carrier family 18 member A2	Homo sapiens	89-94
27821772-7	2016	These experiments provide significant insight into the role of proton translocation in the conformational dynamics of a mammalian H+-coupled antiporter, and also identify key aspects of the mode of action and binding of two potent inhibitors of VMAT2: reserpine binds the cytoplasm-facing conformation, and tetrabenazine binds the lumen-facing conformation.	Tetrabenazine	307-320	solute carrier family 18 member A2	Homo sapiens	245-250
27381871-9	2016	DiHTBZ enantiomers were catalyzed mainly by CYP2C19 and the predicted clearance suggests that liver metabolism is the main route for TBZ elimination which supports the literature data.	Tetrabenazine	3-6	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	44-51
26590367-0	2016	The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.	Tetrabenazine	112-125	monoamine oxidase B	Homo sapiens	4-9
26590367-0	2016	The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.	Tetrabenazine	112-125	solute carrier family 18 member A2	Homo sapiens	95-101
26590367-2	2016	Via inhibition of the vesicular monoamine transporter (VMAT-2), TBZ blocks dopamine (DA) storage and depletes striatal DA; this drug also has been shown to induce Parkinsonian motor side effects in patients.	Tetrabenazine	64-67	solute carrier family 18 member A2	Homo sapiens	55-61
26105139-4	2016	In the present studies the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine (TBZ) were investigated.	Tetrabenazine	106-119	solute carrier family 18 member A2	Homo sapiens	88-94
26105139-4	2016	In the present studies the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine (TBZ) were investigated.	Tetrabenazine	121-124	solute carrier family 18 member A2	Homo sapiens	88-94
24905523-6	2014	Tetrabenazine-treatment (1mg/kg sc) depletes the transmitters from their stores in the nerve terminals of the catecholaminergic neurons and blocks the acquisition of a CAR.	Tetrabenazine	0-13	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	168-171
25323625-0	2015	The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion.	Tetrabenazine	21-34	solute carrier family 18 member A2	Homo sapiens	4-10
25323625-2	2015	Animal tests can model these motivational symptoms, and the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine.	Tetrabenazine	173-186	solute carrier family 18 member A2	Homo sapiens	155-161
25762295-1	2016	Pluripotent stem cells are considered as a cell source for replacement therapies for pancreatic beta cells and other organs.We identified tetrabenazine (TBZ), vesicular monoamine transporter 2 (VMAT2) inhibitor as a promoter of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Ngn3-positive endocrine progenitor cells.	Tetrabenazine	138-151	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	159-192
25762295-1	2016	Pluripotent stem cells are considered as a cell source for replacement therapies for pancreatic beta cells and other organs.We identified tetrabenazine (TBZ), vesicular monoamine transporter 2 (VMAT2) inhibitor as a promoter of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Ngn3-positive endocrine progenitor cells.	Tetrabenazine	138-151	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	194-199
25762295-1	2016	Pluripotent stem cells are considered as a cell source for replacement therapies for pancreatic beta cells and other organs.We identified tetrabenazine (TBZ), vesicular monoamine transporter 2 (VMAT2) inhibitor as a promoter of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Ngn3-positive endocrine progenitor cells.	Tetrabenazine	138-151	pancreatic and duodenal homeobox 1	Mus musculus	258-262
25762295-1	2016	Pluripotent stem cells are considered as a cell source for replacement therapies for pancreatic beta cells and other organs.We identified tetrabenazine (TBZ), vesicular monoamine transporter 2 (VMAT2) inhibitor as a promoter of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Ngn3-positive endocrine progenitor cells.	Tetrabenazine	138-151	neurogenin 3	Mus musculus	305-309
25762295-1	2016	Pluripotent stem cells are considered as a cell source for replacement therapies for pancreatic beta cells and other organs.We identified tetrabenazine (TBZ), vesicular monoamine transporter 2 (VMAT2) inhibitor as a promoter of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Ngn3-positive endocrine progenitor cells.	Tetrabenazine	153-156	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	159-192
25762295-1	2016	Pluripotent stem cells are considered as a cell source for replacement therapies for pancreatic beta cells and other organs.We identified tetrabenazine (TBZ), vesicular monoamine transporter 2 (VMAT2) inhibitor as a promoter of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Ngn3-positive endocrine progenitor cells.	Tetrabenazine	153-156	pancreatic and duodenal homeobox 1	Mus musculus	258-262
25762295-1	2016	Pluripotent stem cells are considered as a cell source for replacement therapies for pancreatic beta cells and other organs.We identified tetrabenazine (TBZ), vesicular monoamine transporter 2 (VMAT2) inhibitor as a promoter of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Ngn3-positive endocrine progenitor cells.	Tetrabenazine	153-156	neurogenin 3	Mus musculus	305-309
25858023-5	2015	METHODS: The effects of ketamine and other NMDAR antagonists to reverse tetrabenazine-induced ptosis were examined and compared with their antidepressant-like effects in the tail suspension test (TST) in mice.	Tetrabenazine	72-85	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	43-48
25858023-6	2015	RESULTS: All the NMDAR antagonists tested produced a partial reversal of tetrabenazine-induced ptosis and, as expected, reduced immobility in the TST.	Tetrabenazine	73-86	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	17-22
25858023-8	2015	CONCLUSION: The ability to reverse tetrabenazine-induced ptosis is a class effect of NMDAR antagonists.	Tetrabenazine	35-48	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	85-90
25759301-1	2015	The cardinal motor symptoms of Parkinson"s disease (PD) include resting tremor, akinesia, bradykinesia, and rigidity, and these motor abnormalities can be modeled in rodents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibitor tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin-2-one; TBZ).	Tetrabenazine	257-270	solute carrier family 18 member A2	Rattus norvegicus	199-205
25467156-1	2014	Dihydrotetrabenazine (DTBZ) derivatized from (+) Tetrabenazine (TBZ) has been used for imaging the expression of VMAT2 when labeled with (11)C (t1/2=20.3 min) or (18)F (t1/2=110 min) in neurodegenerative diseases or pancreatic beta-cell.	Tetrabenazine	45-62	solute carrier family 18 member A2	Rattus norvegicus	113-118
25467156-1	2014	Dihydrotetrabenazine (DTBZ) derivatized from (+) Tetrabenazine (TBZ) has been used for imaging the expression of VMAT2 when labeled with (11)C (t1/2=20.3 min) or (18)F (t1/2=110 min) in neurodegenerative diseases or pancreatic beta-cell.	Tetrabenazine	23-26	solute carrier family 18 member A2	Rattus norvegicus	113-118
24937131-0	2014	The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.	Tetrabenazine	21-34	solute carrier family 18 member A2	Homo sapiens	4-10
24937131-3	2014	Tasks measuring effort-based decision making can be used as animal models of the motivational symptoms of depression, and the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine.	Tetrabenazine	239-252	solute carrier family 18 member A2	Homo sapiens	221-227
24937131-9	2014	The adenosine A2A antagonist MSX-3, the antidepressant and catecholamine uptake inhibitor bupropion, and the MAO-B inhibitor deprenyl, all reversed the impairments induced by tetrabenazine.	Tetrabenazine	175-188	monoamine oxidase B	Homo sapiens	109-114
24018103-4	2013	VMAT2 is also a target of tetrabenazine, a drug used in the treatment of hyperkinetic movement disorders, including TD.	Tetrabenazine	26-39	solute carrier family 18 member A2	Homo sapiens	0-5
24002822-9	2014	Depletion of cellular histamine with tetrabenazine, an inhibitor of vesicular monoamine transporter-2, did not affect granule maturation.	Tetrabenazine	37-50	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	68-101
24305809-9	2013	A behaviorally active dose of tetrabenazine decreased extracellular DA in nucleus accumbens and increased expression of DARPP-32 in accumbens medium spiny neurons in a pattern indicative of reduced transmission at both D1 and D2 DA receptors.	Tetrabenazine	30-43	protein phosphatase 1 regulatory inhibitor subunit 1B	Homo sapiens	120-128
24062308-3	2013	Tetrabenazine (TBZ) is a non-competitive inhibitor of VMAT2 that is used in the treatment of hyperkinetic disorders associated with Huntington disease and Tourette syndrome.	Tetrabenazine	0-13	solute carrier family 18 member A2	Homo sapiens	54-59
24062308-3	2013	Tetrabenazine (TBZ) is a non-competitive inhibitor of VMAT2 that is used in the treatment of hyperkinetic disorders associated with Huntington disease and Tourette syndrome.	Tetrabenazine	15-18	solute carrier family 18 member A2	Homo sapiens	54-59
24062308-5	2013	However, the precise mechanism of TBZ interaction with VMAT2 remains unknown.	Tetrabenazine	34-37	solute carrier family 18 member A2	Homo sapiens	55-60
24062308-10	2013	Our results provide a novel insight into the mechanism of transport and TBZ binding by VMAT2.	Tetrabenazine	72-75	solute carrier family 18 member A2	Homo sapiens	87-92
24316738-3	2014	The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors.	Tetrabenazine	43-56	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	69-102
24316738-3	2014	The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors.	Tetrabenazine	43-56	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	104-109
24316738-3	2014	The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors.	Tetrabenazine	43-56	pancreatic and duodenal homeobox 1	Mus musculus	169-173
24316738-3	2014	The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors.	Tetrabenazine	43-56	neurogenin 3	Mus musculus	216-223
24316738-3	2014	The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors.	Tetrabenazine	43-56	neurogenin 3	Mus musculus	251-255
24316738-3	2014	The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors.	Tetrabenazine	58-61	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	69-102
24316738-3	2014	The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors.	Tetrabenazine	58-61	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	104-109
24316738-3	2014	The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors.	Tetrabenazine	58-61	pancreatic and duodenal homeobox 1	Mus musculus	169-173
24316738-3	2014	The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors.	Tetrabenazine	58-61	neurogenin 3	Mus musculus	216-223
24316738-3	2014	The present study identified reserpine and tetrabenazine (TBZ), both vesicular monoamine transporter 2 (VMAT2) inhibitors, as promoters of late-stage differentiation of Pdx1-positive pancreatic progenitor cells into Neurog3 (referred to henceforth as Ngn3)-positive endocrine precursors.	Tetrabenazine	58-61	neurogenin 3	Mus musculus	251-255
24305809-0	2013	Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.	Tetrabenazine	60-73	solute carrier family 18 member A2	Homo sapiens	43-49
24305809-4	2013	Tetrabenazine produces depressive symptoms in humans and, because of its selective inhibition of VMAT-2, it preferentially depletes dopamine (DA).	Tetrabenazine	0-13	solute carrier family 18 member A2	Homo sapiens	97-103
23280482-0	2013	Analysis of CYP2D6 genotype and response to tetrabenazine.	Tetrabenazine	44-57	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	12-18
24255799-1	2013	BACKGROUND: Although tetrabenazine, a drug that depletes presynaptic dopamine by inhibiting vesicular monoamine transporter 2 (VMAT2), was approved by the U.S. Food and Drug Administration in 2008 for the treatment of chorea associated with Huntington"s disease (HD), there is a paucity of data on its long-term efficacy and safety.	Tetrabenazine	21-34	solute carrier family 18 member A2	Homo sapiens	92-125
24255799-1	2013	BACKGROUND: Although tetrabenazine, a drug that depletes presynaptic dopamine by inhibiting vesicular monoamine transporter 2 (VMAT2), was approved by the U.S. Food and Drug Administration in 2008 for the treatment of chorea associated with Huntington"s disease (HD), there is a paucity of data on its long-term efficacy and safety.	Tetrabenazine	21-34	solute carrier family 18 member A2	Homo sapiens	127-132
23867769-0	2013	The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.	Tetrabenazine	55-68	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	37-43
23867769-5	2013	The adenosine A2A antagonist MSX-3 (1.25-10.0mg/kg) significantly attenuated the TJMs induced by 2.0mg/kg TBZ in rats, and also significantly reduced the display of catalepsy and locomotor suppression induced by TBZ.	Tetrabenazine	106-109	msh homeobox 3	Mus musculus	29-34
23867769-5	2013	The adenosine A2A antagonist MSX-3 (1.25-10.0mg/kg) significantly attenuated the TJMs induced by 2.0mg/kg TBZ in rats, and also significantly reduced the display of catalepsy and locomotor suppression induced by TBZ.	Tetrabenazine	212-215	msh homeobox 3	Mus musculus	29-34
23867769-7	2013	MSX-3 (2.5-10.0mg/kg) also significantly reduced TBZ-induced TJMs in CD1 mice.	Tetrabenazine	49-52	msh homeobox 3	Mus musculus	0-5
23867769-7	2013	MSX-3 (2.5-10.0mg/kg) also significantly reduced TBZ-induced TJMs in CD1 mice.	Tetrabenazine	49-52	CD1 antigen complex	Mus musculus	69-72
23867769-9	2013	TBZ (2.0mg/kg) significantly increased the number of c-Fos-positive cells in the VLS, which is indicative of reduced DA D2 receptor transmission, and 10.0mg/kg MSX-3 significantly attenuated the TBZ-induced c-Fos expression.	Tetrabenazine	0-3	FBJ osteosarcoma oncogene	Mus musculus	53-58
23867769-9	2013	TBZ (2.0mg/kg) significantly increased the number of c-Fos-positive cells in the VLS, which is indicative of reduced DA D2 receptor transmission, and 10.0mg/kg MSX-3 significantly attenuated the TBZ-induced c-Fos expression.	Tetrabenazine	0-3	dopamine receptor D2	Mus musculus	120-131
23867769-9	2013	TBZ (2.0mg/kg) significantly increased the number of c-Fos-positive cells in the VLS, which is indicative of reduced DA D2 receptor transmission, and 10.0mg/kg MSX-3 significantly attenuated the TBZ-induced c-Fos expression.	Tetrabenazine	0-3	FBJ osteosarcoma oncogene	Mus musculus	207-212
23867769-9	2013	TBZ (2.0mg/kg) significantly increased the number of c-Fos-positive cells in the VLS, which is indicative of reduced DA D2 receptor transmission, and 10.0mg/kg MSX-3 significantly attenuated the TBZ-induced c-Fos expression.	Tetrabenazine	195-198	msh homeobox 3	Mus musculus	160-165
23875622-8	2013	These results support a hypothetical model of GZ-793A interaction at more than one site on the VMAT2 protein, which explains its potent inhibition of dopamine uptake, dopamine release via a High-affinity tetrabenazine- and reserpine-sensitive site, dopamine release via a Low-affinity tetrabenazine- and reserpine-insensitive site, and a low-affinity interaction with the dihydrotetrabenazine binding site on VMAT2.	Tetrabenazine	204-217	solute carrier family 18 member A2	Rattus norvegicus	95-100
23875622-8	2013	These results support a hypothetical model of GZ-793A interaction at more than one site on the VMAT2 protein, which explains its potent inhibition of dopamine uptake, dopamine release via a High-affinity tetrabenazine- and reserpine-sensitive site, dopamine release via a Low-affinity tetrabenazine- and reserpine-insensitive site, and a low-affinity interaction with the dihydrotetrabenazine binding site on VMAT2.	Tetrabenazine	285-298	solute carrier family 18 member A2	Rattus norvegicus	95-100
23404442-3	2013	Radiolabelled analogues of tetrabenazine (TBZ; a low-molecular-weight, cell-permeant VMAT2-selective ligand) have been employed for pancreatic islet imaging in humans.	Tetrabenazine	27-40	solute carrier family 18 member A2	Homo sapiens	85-90
23404442-3	2013	Radiolabelled analogues of tetrabenazine (TBZ; a low-molecular-weight, cell-permeant VMAT2-selective ligand) have been employed for pancreatic islet imaging in humans.	Tetrabenazine	42-45	solute carrier family 18 member A2	Homo sapiens	85-90
23280482-2	2013	Following oral administration, tetrabenazine is hepatically transformed into 2 active metabolites that are CYP2D6 substrates.	Tetrabenazine	31-44	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	107-113
23280482-4	2013	CYP2D6 genotyping was performed on sequential subjects treated with tetrabenazine, but results were not known at the time of titration.	Tetrabenazine	68-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
22749259-7	2012	RESULTS: TBZ variably undergoes extensive first-pass metabolism to active metabolites, some of which are metabolized by the cytochrome P450 2D6 isozyme.	Tetrabenazine	9-12	cytochrome P450 2D6	Homo sapiens	124-143
22698664-11	2012	Furthermore, the VMAT2-specific inhibitor tetrabenazine (TBZ) blocks uptake into the mCherry-positive compartment.	Tetrabenazine	42-55	solute carrier family 18 member A2	Homo sapiens	17-22
22698664-11	2012	Furthermore, the VMAT2-specific inhibitor tetrabenazine (TBZ) blocks uptake into the mCherry-positive compartment.	Tetrabenazine	57-60	solute carrier family 18 member A2	Homo sapiens	17-22
22296263-10	2012	To further unmask the mechanics governing extracellular dopamine levels we used intravenous injection of the vesicular monoamine transporter (VMAT2) inhibitor, tetrabenazine, to deplete dopamine storage and increase cytoplasmic dopamine in the nerve terminals.	Tetrabenazine	160-173	solute carrier family 18 member A2	Rattus norvegicus	142-147
22296263-11	2012	Tetrabenazine almost abolished phasic dopamine release but increased extracellular dopamine to ~500 nM, presumably by inducing reverse transport by dopamine transporter (DAT).	Tetrabenazine	0-13	solute carrier family 6 member 3	Rattus norvegicus	148-168
22296263-11	2012	Tetrabenazine almost abolished phasic dopamine release but increased extracellular dopamine to ~500 nM, presumably by inducing reverse transport by dopamine transporter (DAT).	Tetrabenazine	0-13	solute carrier family 6 member 3	Rattus norvegicus	170-173
21669212-7	2011	Results show that TBZ was 11-fold more potent inhibiting DAT than SERT, and 2.5-fold more potent inhibiting VMAT2 than DAT.	Tetrabenazine	18-21	solute carrier family 18 member A2	Rattus norvegicus	108-113
22198452-2	2012	This study examined augmenting response in treatment-resistant schizophrenia through the addition of tetrabenazine (TBZ), a presynaptic vesicular monoamine transporter (VMAT2) inhibitor.	Tetrabenazine	101-114	solute carrier family 18 member A2	Homo sapiens	169-174
22198452-2	2012	This study examined augmenting response in treatment-resistant schizophrenia through the addition of tetrabenazine (TBZ), a presynaptic vesicular monoamine transporter (VMAT2) inhibitor.	Tetrabenazine	116-119	solute carrier family 18 member A2	Homo sapiens	169-174
21982574-0	2011	Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas.	Tetrabenazine	26-39	solute carrier family 18 member A2	Rattus norvegicus	65-70
21669212-1	2011	Tetrabenazine (TBZ), a benzoquinolizine derivative, binds with high affinity to the vesicular monoamine transporter-2 (VMAT2), inhibiting uptake of cytosolic monoamines.	Tetrabenazine	0-13	solute carrier family 18 member A2	Rattus norvegicus	84-117
21669212-7	2011	Results show that TBZ was 11-fold more potent inhibiting DAT than SERT, and 2.5-fold more potent inhibiting VMAT2 than DAT.	Tetrabenazine	18-21	solute carrier family 6 member 3	Rattus norvegicus	119-122
21669212-1	2011	Tetrabenazine (TBZ), a benzoquinolizine derivative, binds with high affinity to the vesicular monoamine transporter-2 (VMAT2), inhibiting uptake of cytosolic monoamines.	Tetrabenazine	0-13	solute carrier family 18 member A2	Rattus norvegicus	119-124
20135628-6	2011	The classical VMAT2 inhibitor, tetrabenazine, has long been used for the treatment of chorea associated with Huntington"s disease in the United Kingdom, Canada, and Australia, and recently approved in the United States.	Tetrabenazine	31-44	solute carrier family 18 member A2	Homo sapiens	14-19
21669212-1	2011	Tetrabenazine (TBZ), a benzoquinolizine derivative, binds with high affinity to the vesicular monoamine transporter-2 (VMAT2), inhibiting uptake of cytosolic monoamines.	Tetrabenazine	15-18	solute carrier family 18 member A2	Rattus norvegicus	84-117
21669212-1	2011	Tetrabenazine (TBZ), a benzoquinolizine derivative, binds with high affinity to the vesicular monoamine transporter-2 (VMAT2), inhibiting uptake of cytosolic monoamines.	Tetrabenazine	15-18	solute carrier family 18 member A2	Rattus norvegicus	119-124
21669212-7	2011	Results show that TBZ was 11-fold more potent inhibiting DAT than SERT, and 2.5-fold more potent inhibiting VMAT2 than DAT.	Tetrabenazine	18-21	solute carrier family 6 member 3	Rattus norvegicus	57-60
21669212-7	2011	Results show that TBZ was 11-fold more potent inhibiting DAT than SERT, and 2.5-fold more potent inhibiting VMAT2 than DAT.	Tetrabenazine	18-21	solute carrier family 6 member 4	Rattus norvegicus	66-70
21273402-6	2011	D1 receptor modulation of sEPSCs was absent in D1-YAC128 cells at the early symptomatic stage but was restored by treating the slices with tetrabenazine.	Tetrabenazine	139-152	dopamine receptor D1	Mus musculus	0-11
21396745-0	2011	Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.	Tetrabenazine	30-43	solute carrier family 18 member A2	Homo sapiens	111-116
21396745-1	2011	Tetrabenazine (TBZ) ((+-)-1) and dihydrotetrabenazines (DHTBZ) are potent inhibitors of VMAT2.	Tetrabenazine	0-13	solute carrier family 18 member A2	Homo sapiens	88-93
21396745-1	2011	Tetrabenazine (TBZ) ((+-)-1) and dihydrotetrabenazines (DHTBZ) are potent inhibitors of VMAT2.	Tetrabenazine	15-18	solute carrier family 18 member A2	Homo sapiens	88-93
20869622-13	2010	TBZ is subject to important drug-drug interactions with inhibitors and inducers of cytochrome P450 (CYP) 2D6, reserpine, and lithium.	Tetrabenazine	0-3	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	83-108
20420689-4	2010	A specific inhibitor of vesicular monoamine transporter (VMAT2) tetrabenazine (TBZ) has been recently approved by Food and Drug Administration for treatment of HD patients in the USA.	Tetrabenazine	64-77	solute carrier family 18 member A2	Homo sapiens	57-62
20442355-9	2010	Tetrabenazine is extensively metabolized hepatically by the CYP2D6 enzyme to its primary active metabolite, alpha-dihydrotetrabenazine.	Tetrabenazine	0-13	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	60-66
20447551-2	2010	C-11- and F-18-labeled tetrabenazine derivatives targeting VMAT2 have shown some promising results as potential biomarkers for BCM.	Tetrabenazine	23-36	solute carrier family 18 member A2	Rattus norvegicus	59-64
20420689-4	2010	A specific inhibitor of vesicular monoamine transporter (VMAT2) tetrabenazine (TBZ) has been recently approved by Food and Drug Administration for treatment of HD patients in the USA.	Tetrabenazine	79-82	solute carrier family 18 member A2	Homo sapiens	57-62
20560567-3	2009	The exo,exo analogue 2 had comparable affinity to lobelane and had greater affinity than the endo,endo analogue 3 at the tetrabenazine binding site on VMAT2, indicating that the preferred binding mode of lobelane is likely the extended conformation.	Tetrabenazine	121-134	solute carrier family 18 member A2	Homo sapiens	151-156
20007701-5	2010	This expression system allowed identification of a new substrate, acriflavine, and isolation of mutants with modified affinity to tetrabenazine (TBZ), a non-competitive inhibitor of VMAT2 that is used in the treatment of various movement disorders including Tourette syndrome and Huntington chorea.	Tetrabenazine	130-143	solute carrier family 18 member A2	Rattus norvegicus	182-187
20007701-5	2010	This expression system allowed identification of a new substrate, acriflavine, and isolation of mutants with modified affinity to tetrabenazine (TBZ), a non-competitive inhibitor of VMAT2 that is used in the treatment of various movement disorders including Tourette syndrome and Huntington chorea.	Tetrabenazine	145-148	solute carrier family 18 member A2	Rattus norvegicus	182-187
20007701-8	2010	The work described here shows that in the case of rVMAT2, loss of traits acquired in evolution of function (such as serotonin transport and TBZ binding) bring about an improvement in older functions such as resistance to toxic compounds.	Tetrabenazine	140-143	solute carrier family 18 member A2	Rattus norvegicus	50-56
20080893-2	2010	METHODS: In this study, a novel (18)F-labeled tetrabenazine derivative, (18)F-(+)fluoropropyldihydrotetrabenazine ((18)F-AV-133), was used for the noninvasive assessment of the vesicular monoamine transporters type 2 (VMAT2) in 17 Parkinson disease (PD) patients and 6 healthy controls.	Tetrabenazine	46-59	solute carrier family 18 member A2	Homo sapiens	177-216
20080893-2	2010	METHODS: In this study, a novel (18)F-labeled tetrabenazine derivative, (18)F-(+)fluoropropyldihydrotetrabenazine ((18)F-AV-133), was used for the noninvasive assessment of the vesicular monoamine transporters type 2 (VMAT2) in 17 Parkinson disease (PD) patients and 6 healthy controls.	Tetrabenazine	46-59	solute carrier family 18 member A2	Homo sapiens	218-223
17383572-7	2007	The binding of [(18)F]FP-(+)-DTBZ to the VMAT2 was shown to be reversible by administration of a competing dose of unlabeled tetrabenazine.	Tetrabenazine	125-138	solute carrier family 18 member A2	Rattus norvegicus	41-46
18577569-0	2008	Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.	Tetrabenazine	134-147	solute carrier family 18 member A2	Rattus norvegicus	8-46
18577569-5	2008	Using a VMAT2-specific antagonist, tetrabenazine (TBZ), we studied glucose homeostasis, insulin secretion both in vivo and ex vivo in cultures of purified rodent islets.	Tetrabenazine	35-48	solute carrier family 18 member A2	Rattus norvegicus	8-13
18577569-5	2008	Using a VMAT2-specific antagonist, tetrabenazine (TBZ), we studied glucose homeostasis, insulin secretion both in vivo and ex vivo in cultures of purified rodent islets.	Tetrabenazine	50-53	solute carrier family 18 member A2	Rattus norvegicus	8-13
17559790-1	2007	Two iodophenylazide derivatives of reserpine and one iodophenylazide derivative of tetrabenazine have been synthesized and characterized as photoaffinity labels of the vesicle monoamine transporter (VMAT2).	Tetrabenazine	83-96	solute carrier family 18 member A2	Homo sapiens	199-204
17559790-8	2007	Incubation of [125I]TBZ-AIPP-photolabeled chromaffin granule membranes in the presence of the glycosidase N-glycanase shifted the apparent molecular weight of VMAT2 to approximately 51 kDa.	Tetrabenazine	20-23	solute carrier family 18 member A2	Homo sapiens	159-164
19052001-1	2008	Tetrabenazine inhibits the transport of a molecule called vesicular monoamine transporter type 2 or VMAT2.	Tetrabenazine	0-13	solute carrier family 18 member A2	Homo sapiens	100-105
18248620-6	2008	Augmented effects of alpha-methyl-para-tyrosine (alphaMT, an inhibitor of TH) and tetrabenazine (VMAT2 blocker) on DA levels suggest that also storage of DA is increased in MEN2B mice.	Tetrabenazine	82-95	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	97-102
18771016-7	2008	Since the activation of the cortical neurons via the noradrenergic neurons in the brain stem is sine qua non for the acquisition for a CAR, rats treated with tetrabenazine are unable to learn in the shuttle box.	Tetrabenazine	158-171	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	135-138
18771016-8	2008	To block the activity of MAO-A (clorgyline) or to treat rats with an enhancer substance [(-)-BPAP] are the two possibilities to antagonize the learning deficit caused by tetrabenazine.	Tetrabenazine	170-183	monoamine oxidase A	Rattus norvegicus	25-30
18771016-12	2008	J-508 and rasagiline proved to be devoid of the enhancer property and in doses which are known to block MAO-A, they antagonized the effect of tetrabenazine, like clorgyline.	Tetrabenazine	142-155	monoamine oxidase A	Rattus norvegicus	104-109
17766642-2	2007	Based on our previous studies using photoaffinity-labeling techniques in characterizing the VMAT2-specific ligands ketanserin and tetrabenazine, this study describes the synthesis and characterization of a fluorenone-based compound, iodoaminoflisopolol (IAmF), as a photoprobe to identify the substrate binding site(s) of VMAT2.	Tetrabenazine	130-143	solute carrier family 18 member A2	Homo sapiens	92-97
17766642-7	2007	Sf9 vesicles expressing VMAT2 show reserpine- and tetrabenazine-protectable photolabeling by [125I]IAmF.	Tetrabenazine	50-63	solute carrier family 18 member A2	Homo sapiens	24-29
11489261-11	2001	In other studies, we demonstrated that the VMAT2 inhibitors tetrabenazine and Ro 4-1284 inhibit P-GP and that the P-GP inhibitors trans-flupentixol and quinidine inhibit VMAT2.	Tetrabenazine	60-73	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	43-48
16934687-8	2006	Results of in vitro autoradiography with [(18)F]6b showed a distinct binding in the caudate putamen region consistent with the localization of VMAT2 in the mouse brain, which was blocked by nonradioactive TBZ efficiently.	Tetrabenazine	205-208	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	143-148
16480775-5	2006	Vesicular DA uptake was temperature- and ATP-dependent and was blocked by the VMAT-2 inhibitor tetrabenazine.	Tetrabenazine	95-108	solute carrier family 18 member A2	Rattus norvegicus	78-84
11984859-2	2002	Paired studies were done comparing baseline vs. TBZ treatment on the uptake of FDOPA, a measure of aromatic L-amino acid decarboxylase (AAAD) activity.	Tetrabenazine	48-51	dopa decarboxylase	Macaca mulatta	99-134
11984859-3	2002	Results show increased AAAD activity with TBZ treatment.	Tetrabenazine	42-45	dopa decarboxylase	Macaca mulatta	23-27
11984859-5	2002	Results also showed diminished responsivity of AAAD to TBZ challenge in aged monkey brain.	Tetrabenazine	55-58	dopa decarboxylase	Macaca mulatta	47-51
11841781-5	2002	Reevaluation of the mechanism by which lobeline alters dopamine function reveals that its primary mechanism is inhibition of dopamine uptake and promotion of dopamine release from the storage vesicles within the presynaptic terminal, via an interaction with the tetrabenazine-binding site on the vesicular monoamine transporter (VMAT2).	Tetrabenazine	262-275	solute carrier family 18 member A2	Rattus norvegicus	329-334
14757360-6	2004	Transport by rVMAT2-I483A/L484A-injected oocytes was reduced to control levels by tetrabenazine, a known inhibitor of VMAT transport activity.	Tetrabenazine	82-95	solute carrier family 18 member A2	Rattus norvegicus	13-19
11669473-11	2001	Only the VMAT2 blockers tetrabenazine and reserpine inhibited [3H]TBZOH specific binding.	Tetrabenazine	24-37	solute carrier family 18 member A2	Homo sapiens	9-14
11489261-11	2001	In other studies, we demonstrated that the VMAT2 inhibitors tetrabenazine and Ro 4-1284 inhibit P-GP and that the P-GP inhibitors trans-flupentixol and quinidine inhibit VMAT2.	Tetrabenazine	60-73	phosphoglycolate phosphatase	Mus musculus	96-100
11375404-0	2001	Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport.	Tetrabenazine	133-146	solute carrier family 18 member A2	Homo sapiens	40-71
11375404-0	2001	Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport.	Tetrabenazine	133-146	solute carrier family 18 member A2	Homo sapiens	73-78
10415365-0	1999	Ketanserin and tetrabenazine abolish aggression in mice lacking monoamine oxidase A.	Tetrabenazine	15-28	monoamine oxidase A	Mus musculus	64-83
10415365-3	1999	Our results show that ketanserin and tetrabenazine (TBZ) strikingly abolished the aggressive behavior of MAO A-deficient mice.	Tetrabenazine	37-50	monoamine oxidase A	Mus musculus	105-110
10415365-3	1999	Our results show that ketanserin and tetrabenazine (TBZ) strikingly abolished the aggressive behavior of MAO A-deficient mice.	Tetrabenazine	52-55	monoamine oxidase A	Mus musculus	105-110
10415365-6	1999	Ketanserin and TBZ are both antagonists of the vesicular monoamine transporter (VMAT2).	Tetrabenazine	15-18	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	80-85
10415365-7	1999	The anti-aggressive effect of TBZ and part of the effect of ketanserin may be mediated by the VMAT2.	Tetrabenazine	30-33	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	94-99
9480916-7	1998	Photoaffinity labelling of rVMAT2 by 1 nM [125I]AZIK was protectable by 10 microM tetrabenazine and 10 microM 7-aminoketanserin.	Tetrabenazine	82-95	solute carrier family 18 member A2	Rattus norvegicus	27-33
9325342-4	1997	Both [125I]AZIK and [125I]TBZ-AIPP photoaffinity labeling of purified rVMAT2 were protectable by 10 microM tetrabenazine (TBZ), 10 microM 7-aminoketanserin, and 1 mM concentrations of the transporter substrates dopamine, norepinephrine, and serotonin.	Tetrabenazine	107-120	solute carrier family 18 member A2	Rattus norvegicus	70-76
9461580-2	1998	The neuronal VMAT2 exhibits a higher affinity for monoamine substrates and in particular for histamine as well as a greater sensitivity to the inhibitor tetrabenazine than the nonneuronal VMAT1.	Tetrabenazine	153-166	solute carrier family 18 member A2	Homo sapiens	13-18
9461580-4	1998	Using site-directed mutagenesis to replace residues in TMD5-8 of VMAT2 with the equivalent residues from VMAT1, we now show that the sensitivity of VMAT2 to tetrabenazine requires Ala-315, and this interaction occurs independently of the interaction with residues in TMD9-12.	Tetrabenazine	157-170	solute carrier family 18 member A2	Homo sapiens	65-70
9461580-4	1998	Using site-directed mutagenesis to replace residues in TMD5-8 of VMAT2 with the equivalent residues from VMAT1, we now show that the sensitivity of VMAT2 to tetrabenazine requires Ala-315, and this interaction occurs independently of the interaction with residues in TMD9-12.	Tetrabenazine	157-170	solute carrier family 18 member A1	Homo sapiens	105-110
9461580-4	1998	Using site-directed mutagenesis to replace residues in TMD5-8 of VMAT2 with the equivalent residues from VMAT1, we now show that the sensitivity of VMAT2 to tetrabenazine requires Ala-315, and this interaction occurs independently of the interaction with residues in TMD9-12.	Tetrabenazine	157-170	solute carrier family 18 member A2	Homo sapiens	148-153
9325342-4	1997	Both [125I]AZIK and [125I]TBZ-AIPP photoaffinity labeling of purified rVMAT2 were protectable by 10 microM tetrabenazine (TBZ), 10 microM 7-aminoketanserin, and 1 mM concentrations of the transporter substrates dopamine, norepinephrine, and serotonin.	Tetrabenazine	26-29	solute carrier family 18 member A2	Rattus norvegicus	70-76
9106255-3	1997	However, tetrabenazine is a much less potent inhibitor of transport by rVMAT1, a form of the transporter cloned from a rat pheochromocytoma (PC12) cDNA library and expressed in CHO cells.	Tetrabenazine	9-22	solute carrier family 18 member A1	Rattus norvegicus	71-77
9195934-2	1997	Functional analysis has previously shown that VMAT2 has a higher affinity than VMAT1 for monoamine neurotransmitters as well as the inhibitor tetrabenazine.	Tetrabenazine	142-155	solute carrier family 18 member A2	Homo sapiens	46-51
9195934-8	1997	The mutation K446Q reduced the affinity of VMAT2 for tetrabenazine and serotonin but not histamine, whereas F464Y reduced serotonin affinity and perhaps histamine recognition but not tetrabenazine sensitivity, providing more evidence for specificity.	Tetrabenazine	53-66	solute carrier family 18 member A2	Homo sapiens	43-48
9195934-12	1997	Surprisingly, the residue responsible for this difference, Tyr-434, also accounts for the higher affinity interaction of VMAT2 with tetrabenazine, histamine, and serotonin.	Tetrabenazine	132-145	solute carrier family 18 member A2	Homo sapiens	121-126
9106255-11	1997	These results provide direct evidence that the differential sensitivity of rat brain and adrenal catecholamine stores to depletion by tetrabenazine and its derivatives is due to a much lower affinity of rVMAT1 for these compounds, and that NGF treatment may increase levels of rVMAT1 expression in PC12 cells.	Tetrabenazine	134-147	solute carrier family 18 member A1	Rattus norvegicus	203-209
9045996-4	1997	Saturation binding of [125I]TBZ in striatal membranes demonstrated a single high affinity site (Kd = 2.3 +/- 0.9 nM and Bmax = 55.5 +/- 8.1 pmol/g tissue) with a pharmacological profile (tetrabenazine > or = iodovinyltetrabenazine > ketanserin > or = reserpine > haloperidol > GBR 12909) consistent with the specific labeling of hVMAT2.	Tetrabenazine	28-31	solute carrier family 18 member A2	Homo sapiens	344-350
9080483-1	1997	The recovery of in vivo binding sites for (+/-)-alpha-[11C] methoxytetrabenazine, a radioligand for the monoamine vesicular transporter (VMAT2), was determined in mouse brain at various times following a pharmacological dose of tetrabenazine.	Tetrabenazine	67-80	solute carrier family 18 (vesicular monoamine), member 2	Mus musculus	137-142
8662678-0	1996	Modification of the pH profile and tetrabenazine sensitivity of rat VMAT1 by replacement of aspartate 404 with glutamate.	Tetrabenazine	35-48	solute carrier family 18 member A1	Rattus norvegicus	68-73
8643547-10	1996	Reserpine and ketanserin are slightly more potent inhibitors of VMAT2-mediated transport than of VMAT1-mediated transport, whereas tetrabenazine binds to and inhibits only VMAT2.	Tetrabenazine	131-144	solute carrier family 18 member A2	Homo sapiens	172-177
8621690-4	1996	Two domains of VMAT2, one extending from transmembrane domain (TMD) 5 to the beginning of TMD8 and the other from the end of TMD9 through TMD12, increase the affinity for serotonin and histamine as well as the sensitivity to tetrabenazine but only in the context of more C-terminal and more N-terminal VMAT2 sequences, respectively.	Tetrabenazine	225-238	solute carrier family 18 member A2	Homo sapiens	15-20
8621690-4	1996	Two domains of VMAT2, one extending from transmembrane domain (TMD) 5 to the beginning of TMD8 and the other from the end of TMD9 through TMD12, increase the affinity for serotonin and histamine as well as the sensitivity to tetrabenazine but only in the context of more C-terminal and more N-terminal VMAT2 sequences, respectively.	Tetrabenazine	225-238	solute carrier family 18 member A2	Homo sapiens	302-307
8621690-5	1996	In addition, the extreme N terminus of VMAT2 alone suffices to confer a partial increase in substrate affinity and tetrabenazine sensitivity.	Tetrabenazine	115-128	solute carrier family 18 member A2	Homo sapiens	39-44
8860238-2	1995	Transport of (3)H-histamine by both VMAT1 and VMAT2 was reserpine-sensitive but only transport by VMAT2 was inhibited by tetrabenazine.	Tetrabenazine	121-134	solute carrier family 18 member A2	Rattus norvegicus	98-103